Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura

• Status: Withdrawn
• Trial end date: 2012-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Congenital thrombotic thrombocytopenic purpura (TTP), also called Upshaw-Schulman Syndrome or hereditary or familial TTP is a rare, but severe disease. The purpose of this study is to determine how infusions of plasma to patients with congenital TTP correlate with symptoms and signs of activity of the disease, and to determine why some patients need more frequent infusions of plasma than others to prevent acute attacks of the disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: St. Olavs Hospital
• Collaborator: Norwegian University of Science and Technology

Criteria

Inclusion Criteria:

• Confirmed diagnosis of congenital TTP

• On regular prophylactic plasma treatment: > Once weekly (group 1) or >1 <3 times monthly (group 2)

• Between 18 and 65 years

• Capable of understanding and complying with the protocol

Exclusion Criteria:

• Pregnancy

• Acute bout of TTP requiring daily plasma infusions or -exchange for more than 3 days, within the last 2 weeks before intervention period